Literature DB >> 10695671

Resorcylic acid lactones: naturally occurring potent and selective inhibitors of MEK.

A Zhao1, S H Lee, M Mojena, R G Jenkins, D R Patrick, H E Huber, M A Goetz, O D Hensens, D L Zink, D Vilella, A W Dombrowski, R B Lingham, L Huang.   

Abstract

A resorcylic acid lactone, L-783,277, isolated from a Phoma sp. (ATCC 74403) which came from the fruitbody of Helvella acetabulum, is a potent and specific inhibitor of MEK (Map kinase kinase). L-783,277 inhibits MEK with an IC50 value of 4 nM. It weakly inhibits Lck and is inactive against Raf, PKA and PKC. L-783,277 is an irreversible inhibitor of MEK and is competitive with respect to ATP. L-783,290, the trans-isomer of L-783,277, was isolated from the same culture and evaluated together with several semi-synthetic resorcylic acid lactone analogs. A preliminary structure-activity relationship is presented. Several independent cell-based assays have been carried out to study the biological activities of these resorcylic acid lactone compounds and a brief result summary from these studies is presented.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10695671     DOI: 10.7164/antibiotics.52.1086

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  17 in total

Review 1.  Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets.

Authors:  D W Hommes; M P Peppelenbosch; S J H van Deventer
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Total synthesis of LL-Z1640-2 utilizing a late-stage intramolecular Nozaki-Hiyama-Kishi reaction.

Authors:  Christopher A Leclair; Matthew B Boxer; Craig J Thomas; David J Maloney
Journal:  Tetrahedron Lett       Date:  2010-12-29       Impact factor: 2.415

3.  Kinase inhibition by deoxy analogues of the resorcylic lactone L-783277.

Authors:  Marc Liniger; Christian Neuhaus; Tatjana Hofmann; Luca Fransioli-Ignazio; Michel Jordi; Peter Drueckes; Jörg Trappe; Doriano Fabbro; Karl-Heinz Altmann
Journal:  ACS Med Chem Lett       Date:  2010-10-20       Impact factor: 4.345

4.  BRAF mutation predicts sensitivity to MEK inhibition.

Authors:  David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose M Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Sebolt-Leopold; William R Sellers; Neal Rosen
Journal:  Nature       Date:  2005-11-06       Impact factor: 49.962

5.  Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.

Authors:  Juan Manuel Domínguez; Ana Fuertes; Leyre Orozco; María del Monte-Millán; Elena Delgado; Miguel Medina
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

6.  Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets.

Authors:  Jin Xu; Anqi Chen; Mei-Lin Go; Kassoum Nacro; Boping Liu; Christina L L Chai
Journal:  ACS Med Chem Lett       Date:  2011-07-17       Impact factor: 4.345

7.  Genes for the biosynthesis of the fungal polyketides hypothemycin from Hypomyces subiculosus and radicicol from Pochonia chlamydosporia.

Authors:  Christopher D Reeves; Zhihao Hu; Ralph Reid; James T Kealey
Journal:  Appl Environ Microbiol       Date:  2008-06-20       Impact factor: 4.792

Review 8.  Recent progress regarding the bioactivities, biosynthesis and synthesis of naturally occurring resorcinolic macrolides.

Authors:  Jing Xu; Cheng-shi Jiang; Zai-long Zhang; Wen-quan Ma; Yue-wei Guo
Journal:  Acta Pharmacol Sin       Date:  2014-01-27       Impact factor: 6.150

9.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Authors:  Andreas Schirmer; Jonathan Kennedy; Sumati Murli; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

10.  Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways.

Authors:  Carlos García-Echeverría
Journal:  Purinergic Signal       Date:  2008-06-04       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.